Search

Your search keyword '"Lebbe, Celeste"' showing total 205 results

Search Constraints

Start Over You searched for: Author "Lebbe, Celeste" Remove constraint Author: "Lebbe, Celeste" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
205 results on '"Lebbe, Celeste"'

Search Results

1. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

2. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

3. Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline – update 2024

4. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma

5. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024

6. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024

7. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

9. When to stop immunotherapy for advanced melanoma: the emulated target trials

10. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

11. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

14. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

15. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

16. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

17. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

18. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

19. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

20. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

24. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease

26. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

27. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review

28. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors

29. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

30. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases

31. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

32. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

33. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

35. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

36. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

37. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

39. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

40. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

41. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

42. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

43. Hematological immune related adverse events after treatment with immune checkpoint inhibitors

47. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

48. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

50. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019

Catalog

Books, media, physical & digital resources